Cinven is selling its stake in Swedish in-vitro allergy diagnostics company, Phadia Group. The European private equity firm will obtain a total of around €2.47 billion from the transaction. U.S. large life sciences supply company, Thermo Fisher Scientific, will be the new owner of Phadia. Cinven’s healthcare team paid a total of €1.285 billion for the acquisition of Phadia in early 2007.
Click here for the release from Cinven.